Kiora Pharmaceuticals Announces Private Placement of Common Stock and Warrants
Kiora Pharmaceuticals entered into a Securities Purchase Agreement to sell shares of common stock, pre-funded warrants, and common warrants in a private placement. The offering relies on exemptions from securities registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, indicating a transaction with accredited investors.
Key Highlights
- Agreement includes the sale of common stock, pre-funded warrants, Tranche A-1 warrants, and Tranche A-2 warrants.
- The private placement is exempt from securities registration under Section 4(a)(2) and Rule 506 of Regulation D.
- A Registration Rights Agreement will be executed to provide registration rights for the shares and warrant shares.
Price Impact
More from KPRX
More in Equity Offering
One & one Green Technologies Secures $13M in Follow-on Offering from Institutional Investors, with Option for Additional $3M
Linkers Industries Completes Full Exercise of Series B Cashless Warrants, Resulting in 1.52M Class A Shares Outstanding
Annovis Bio Secures $10M Public Offering, Extends Cash Runway to Q2 2027, Funds NDA Submission with AD Phase 3 Trial 75% Enrolled